The European Union’s regulatory framework for veterinary medicines is undergoing its most significant structural overhaul in decades. Driven by the foundational mandates of Regulation (EU) 2019/6, the European Commission is officially enforcing Commission Implementing Regulations (EU) 2025/2091 (for finished products) and (EU) 2025/2154 (for active substances).
Effective July 16, 2026, this transition completely decouples veterinary manufacturing from human pharmaceutical guidelines. For UK-based manufacturers and Marketing Authorisation Holders (MAHs) exporting to the European market, establishing a proactive transition roadmap is essential to protect trade channels and ensure uninterrupted compliance.
The Enforceable Deadline: July 16, 2026
The historical era of shared Good Manufacturing Practice (GMP) guidelines for human and veterinary treatments under EudraLex Volume 4 has officially ended. From July 16, 2026, all veterinary medicinal products (VMPs) distributed within or imported into the EU must strictly comply with the new veterinary-specific regulations.
Because these updates take the form of Implementing Regulations, they carry immediate, binding legal power across all EU member states without requiring local national transposition. Operations currently aligned with legacy Volume 4 parameters must immediately execute comprehensive gap analyses against the Commission’s official correspondence tables to isolate and remediate quality system deficiencies before the enforcement deadline.
Transitioning from Volume 4 to Legally Binding Codification
The most profound shift introduced by Regulation (EU) 2025/2091 is not mechanical, but legal. The regulatory language has officially transitioned from flexible, interpretive recommendations (“should”) to absolute statutory mandates (“shall”).
While the fundamental technical architecture remains heavily aligned with previous expectations, the new framework codifies specialized veterinary requirements into isolated, legally enforceable annexes:
- Annex I: Sterile products and advanced aseptic manufacturing controls.
- Annex II: Biological and immunological veterinary medicinal products (such as cell therapies and viral-based vaccines).
- Annex III: Adjusted specific requirements for specialized dosages, including topicals, medicinal gases, and homeopathic VMPs.
Manufacturers must systematically update their Quality Management Systems (QMS), validation protocols, and Site Master Files (SMF) to mirror these standalone legal categories.
Mandatory Contractual Realignment for MAHs and CDMOs
Regulation (EU) 2025/2091 introduces a dedicated, standalone article that radically expands the legal responsibilities of the Marketing Authorisation Holder (MAH)—especially when manufacturing is outsourced to a third-party CDMO. Under the new rules, the MAH bears direct legal liability for production oversight.
MAHs must formally execute comprehensive technical quality agreements that enforce three strict pillars:
- Continuous Specification Alignment: Guaranteeing that all master manufacturing instructions provided to the plant perfectly match the active marketing authorization file.
- Immediate Variation Communication: Establishing hard operational protocols to convey approved or submitted regulatory variations to production lines without delay.
- Mandatory Product Quality Review (PQR) Evaluation: Compelling the MAH to personally audit the annual PQR metrics generated by the contract facility and legally dictate required CAPA implementations.
Conclusion
The implementation of Regulation (EU) 2025/2091 fundamentally transforms veterinary manufacturing from a secondary branch of human pharma guidance into an independent, rigorously enforced legal regime. For UK manufacturers looking to safeguard their European market footprint past July 2026, success relies on prompt gap assessments, aggressive QMS updates, and the immediate execution of legally binding technical agreements with all supply chain partners.
FAQs
- Does this regulation apply to existing products?
In fact, all veterinary procedures now used in the EU, which were authorised prior to the entry into force of the 2023 Regulation, would instead be valid for a period of five years post the 2026 deadline. - Can I still use the same facility for human and veterinary drugs?
The establishment needs to fulfil all of its required veterinary needs before it will become operational. Segregation, documentation, and quality systems require modifications to achieve compliance with Annexes 1 and 2. - What happens if we miss the July 2026 deadline?
Non-compliance will lead to two specific outcomes, which include suspension of manufacturing authorisation, product supply delays and regulatory penalties. The organisation needs to take immediate action because any delays will disrupt its operational activities.
